Advertisement

Neurologic Manifestations of Gastrointestinal and Liver Diseases

  • José M. FerroEmail author
  • Sofia Oliveira
Neurology of Systemic Disease (J Biller, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neurology of Systemic Disease

Abstract

Hepatic and gastrointestinal disorders can produce a wide spectrum of neurologic complications both affecting the central nervous system (CNS) and the peripheral nervous system. These manifestations range in severity from coma in acute liver failure and acute pancreatitis, to minor cognitive changes in chronic portosystemic encephalopathy and hepatitis C. Cerebrovascular diseases can complicate hepatitis C infection and inflammatory bowel disease. Demyelinating disorders may co-exist with inflammatory bowel disease. Anti-tumor necrosis factor alpha drugs may induce demyelination. Ataxia may occur in malabsorption syndromes and in gluten related disorders. Characteristic movement disorders are key features of acquired hepatocerebral degeneration and of Whipple disease. Multiple types of neuropathy can be found in association with hepatitis, inflammatory bowel disease and gluten related disorders.

Keywords

Hepatic failure Hepatitis Pancreatitis Inflammatory bowel disease Celiac disease Whipple disease Gluten ataxia Central nervous system Peripheral nervous system 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

José M. Ferro and Sofia Oliveira declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369:2525–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Datar S, Wijdicks EF. Neurologic manifestations of acute liver failure. Handb Clin Neurol. 2014;120:645–59.PubMedCrossRefGoogle Scholar
  3. 3.•
    Scott TR, Kronsten VT, Hughes RD, Shawcross DL. Pathophysiology of cerebral oedema in acute liver failure. World J Gastroenterol. 2013;19:9240–55. A comprehensive basic science review of the pathophysiology of liver failure and hepatic encephalopathy.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Weissenborn K. Portosystemic encephalopathy. Handb Clin Neurol. 2014;120:661–74.PubMedCrossRefGoogle Scholar
  5. 5.
    Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Leise MD, Poterucha JJ, Kamath PS, Kim WR. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc. 2014;89:241–53.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.•
    Nardone R, Höller Y, Storti M, et al. Spinal cord involvement in patients with cirrhosis. World J Gastroenterol. 2014;20:2578–85. A clinically oriented review of this rare complication of chronic hepatic failure.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Renjen PN, Khanna L, Rastogi R, Khan NI. Acquired hepatocerebral degeneration. BMJ Case Rep. 2013. doi: 10.1136/bcr-2013-009387.
  9. 9.
    Ferrara J, Jankovic J. Acquired hepatocerebral degeneration. J Neurol. 2009;256:320–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Fernández-Rodriguez R, Contreras A, De Villoria JG, Grandas F. Acquired hepatocerebral degeneration: clinical characteristics and MRI findings. Eur J Neurol. 2010;17:1463–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Maffeo E, Montuschi A, Stura G, Giordana MT. Chronic acquired hepatocerebral degeneration, pallidal T1 MRI hyperintensity and manganese in a series of cirrhotic patients. Neurol Sci. 2014;35:523–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Junker AE, Als-Nielsen B, Gluud C, Gluud LL. Dopamine agents for hepatic encephalopathy. Cochrane Database Syst Rev. 2014;2, CD003047.PubMedGoogle Scholar
  13. 13.•
    Stracciari A, Baldin E, Cretella L, et al. Chronic acquired hepatocerebral degeneration: effects of liver transplantation on neurological manifestations. Neurol Sci. 2011;32:411–5. A case series of 3 patients with acquired hepatocerebral degeneration who received hepatic transplant showing improvement in 2 of them.PubMedCrossRefGoogle Scholar
  14. 14.
    El Moutawakil B, Bourezgui M, Rafai MA, et al. Acute disseminated encephalomyelitis associated with hepatitis A virus infection. Rev Neurol (Paris). 2008;164:852–4.CrossRefGoogle Scholar
  15. 15.
    Yimam KK, Merriman RB, Todd FR. A rare case of acute hepatitis B virus infection causing Guillain-Barre syndrome. Gastroenterol Hepatol (NY). 2013;9:121–3.Google Scholar
  16. 16.
    Mehndiratta M, Pandey S, Nayak R, Saran RK. Acute onset distal symmetrical vasculitic polyneuropathy associated with acute hepatitis B. J Clin Neurosci. 2013;20:331–2.PubMedCrossRefGoogle Scholar
  17. 17.•
    Monaco S, Ferrari S, Gajofatto A, et al. HCV-related nervous system disorders. Clin Dev Immunol. 2012;2012:236148. An extensive review of the mechanisms and clinical aspects of HCV neurologic complications.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Adinolfi LE, Zampino R, Restivo L, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410–7.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Huang H, Kang R, Xhao Z. Hepatitis C vírus infection and risk of stroke: a systematic review and meta-analysis. PloS One. 2013;8(11):e81305.CrossRefGoogle Scholar
  20. 20.
    Ahmad D, Ilias Basha H, Towfiq B, Bachuwa G. Resolution of neurological deficits secondary to spontaneous intracranial haemorrhage and posterior reversible encephalopathy syndrome (PRES) in a patient with hepatitis C-associated cryoglobulinaemia: a role for plasmapheresis. BMJ Case Rep. 2014;2014.Google Scholar
  21. 21.•
    Cheung MC, Maguire J, Carey I, et al. Review of the neurological manifestations of hepatitis E infection. Ann Hepatol. 2012;11:618–22. A literature review of 25 cases of patients with hepatitis E and neurologic manifestations.PubMedGoogle Scholar
  22. 22.•
    Hornik A, Rodriguez Porcel FJ, Agha C, et al. Central and extrapontine myelinolysis affecting the brain and spinal cord. An unusual presentation of pancreatic encephalopathy. Front Neurol. 2012;3:135. Case report of a woman with pancreatitis, encephalopathy and pontine and extrapontine myelinolysis.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Estrada RV, Moreno J, Martinez E, et al. Pancreatic encephalopathy. Acta Neurol Scand. 1979;59:135–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Arana-Guajardo AC, Cámara-Lemarroy CR, Rendón-Ramírez EJ, et al. Wernicke encephalopathy presenting in a patient with severe acute pancreatitis. JOP. 2012;13:104–7.PubMedGoogle Scholar
  25. 25.
    Ahrens CL, Manno EM. Neurotoxicity of commonly used hepatic drugs. Handb Clin Neurol. 2014;120:675–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Ferro JM, Oliveira SN, Correia L. Neurologic manifestations of inflammatory bowel diseases. Handb Clin Neurol. 2014;120:595–605.PubMedCrossRefGoogle Scholar
  27. 27.
    Oliveira GR, Teles BC, Brasil EF, et al. Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients. Inflamm Bowel Dis. 2008;14:389–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Gondim FA, Brannagan TH, Sander HW, et al. Peripheral neuropathy in patients with inflammatory bowel disease. Brain. 2005;128:867–79.PubMedCrossRefGoogle Scholar
  29. 29.
    Canero A, Parmeggiani D, Avenia N, et al. Thromboembolic tendency (TE) in IBD (Inflammatory bowel disease) patients. Ann Ital Chir. 2012;83:313–7.PubMedGoogle Scholar
  30. 30.
    Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60:937–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Barclay AR, Keightley JM, Horrocks I, et al. Cerebral thromboembolic events in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:677–83.PubMedCrossRefGoogle Scholar
  32. 32.
    Benavente L, Morís G. Neurologic disorders associated with inflammatory bowel disease. Eur J Neurol. 2011;18:138–43.PubMedCrossRefGoogle Scholar
  33. 33.•
    Cognat E, Crassard I, Denier C, et al. Cerebral venous thrombosis in inflammatory bowel diseases: eight cases and literature review. Int J Stroke. 2011;6:487–92. A case series of 8 patients cerebral venous thrombosis associated with inflammatory bowel diseases followed by a literature review.PubMedCrossRefGoogle Scholar
  34. 34.
    Bermejo PE, Burgos A. Neurological complications of inflammatory bowel disease. Med Clin (Barc). 2008;130:666–75.CrossRefGoogle Scholar
  35. 35.
    Kreuzpaintner G, Horstkotte D, Heyll A, et al. Increased risk of bacterial endocarditis in inflammatory bowel disease. Am J Med. 1992;92:391–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Chentanez T, Khawcharoenporn T, Chokrungvaranon N, et al. Cardiobacterium hominis endocarditis presenting as acute embolic stroke: a case report and review of the literature. Heart Lung. 2011;40:262–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Gobron C, Kaci R, Sokol H, et al. Unilateral carotid granulomatous arteritis and Crohn's disease. Rev Neurol (Paris). 2010;166:542–6.CrossRefGoogle Scholar
  38. 38.
    Nudelman RJ, Rosen DG, Rouah E, Verstovsek G. Cerebral sinus thrombosis: a fatal neurological complication of ulcerative colitis. Pathol Res Int. 2010;2010:132754.CrossRefGoogle Scholar
  39. 39.
    Casella G, Spreafico C, Costantini M, et al. Cerebral sinus thrombosis in ulcerative colitis. Inflamm Bowel Dis. 2011;17:2214–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Katsanos AH, Katsanos KH, Kosmidou M, et al. Cerebral sinus venous thrombosis in inflammatory bowel diseases. QJM. 2012;106:401–13.PubMedCrossRefGoogle Scholar
  41. 41.
    Tsujikawa T, Urabe M, Bamba H, et al. Haemorrhagic cerebral sinus thrombosis associated with ulcerative colitis: a case report of successful treatment by anticoagulant therapy. J Gastroenterol Hepatol. 2000;15:688–92.PubMedCrossRefGoogle Scholar
  42. 42.
    Philips MF, Bagley LJ, Sinson GP, et al. Endovascular thrombolysis for symptomatic cerebral venous thrombosis. J Neurosurg. 1999;90:65–71.PubMedCrossRefGoogle Scholar
  43. 43.
    Kothur K, Kaul S, Rammurthi S, et al. Use of thrombolytic therapy in cerebral venous sinus thrombosis with ulcerative colitis. Ann Indian Acad Neurol. 2012;15:35–8.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Rang EH, Brooke BN, Hermon-Taylor J. Association of ulcerative colitis with multiple sclerosis. Lancet. 1982;2:555.PubMedCrossRefGoogle Scholar
  45. 45.
    Pandian JD, Pawar G, Singh GS, et al. Multiple sclerosis in a patient with chronic ulcerative colitis. Neurol India. 2004;52:282–3.PubMedGoogle Scholar
  46. 46.
    Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827–36.PubMedCrossRefGoogle Scholar
  47. 47.
    Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005;129:819–26.PubMedCrossRefGoogle Scholar
  48. 48.
    Thomas Jr CW, Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis. 2004;10:28–31.PubMedCrossRefGoogle Scholar
  49. 49.
    Freeman HJ, Flak B. Demyelination-like syndrome in Crohn’s disease after infliximab therapy. Can J Gastroenterol. 2005;19:313–6.PubMedGoogle Scholar
  50. 50.
    Sacher M, Göpfrich H, Hochberger O. Crohn's disease penetrating into the spinal canal. Acta Paediatr Scand. 1989;78:647–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Hershkowitz S, Link R, Ravden M, Lipow K. Spinal empyema in Crohn's disease. J Clin Gastroenterol. 1990;12:67–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Heidemann J, Spinelli KS, Otterson MF, Binion DG. Case report: magnetic resonance imaging in the diagnosis of epidural abscess complicating perirectal fistulizing Crohn's disease. Inflamm Bowel Dis. 2003;9:122–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Laplante P, Vanase M, Michaud J, et al. A progressive neurological syndrome associated with an isolated vitamin E deficiency. Can J Neurol Sci. 1984;11(4 Suppl):561–4.PubMedGoogle Scholar
  54. 54.
    Ayuso Blanco T, Martin Martinez J, Figueras P, et al. Chronic polyneuropathy due to vitamin E deficiency. Neurologia. 1994;9:300–2.PubMedGoogle Scholar
  55. 55.
    Rino Y, Suzuki Y, Kuroiwa Y, et al. Vitamin E malabsorption and neurological consequences after gastrectomy for gastric cancer. Hepato–Gastroenterol. 2007;54:1858–61.Google Scholar
  56. 56.
    Ueda N, Suzuki Y, Rino Y, et al. Correlation between neurological dysfunction with vitamin E deficiency and gastrectomy. J Neurol Sci. 2009;287:216–20.PubMedCrossRefGoogle Scholar
  57. 57.
    Sokol RJ, Kim YS, Hoofnagle JH, et al. Intestinal malabsorption of vitamin E in primary biliary cirrhosis. Gastroenterology. 1989;96:479–86.PubMedGoogle Scholar
  58. 58.
    Yokota T, Tsuchiya K, Furukawa T, et al. Vitamin E deficiency in acquired fat malabsorption. J Neurol. 1990;237:103–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Aslam A, Misbah SA, Talbot K, et al. Vitamin E deficiency induced neurological disease in common variable immunodeficiency: two cases and review of literature of vitamin E deficiency. Clin Immunol. 2004;112:24–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Howard L, Ovesen L, Satya-Murti S, et al. Reversible neurological symptoms caused by vitamin E deficiency in a patient with short bowel syndrome. Am J Clin Nutr. 1982;36:1243–9.PubMedGoogle Scholar
  61. 61.
    Vorgerd M, Tegenthoff M, Kühne D, et al. Spinal MRI in progressive myeloneuropathy associated with vitamin E deficiency. Neuroradiology. 1996;38 Suppl 1:S111–3.PubMedCrossRefGoogle Scholar
  62. 62.
    Bye AM, Muller DP, Wilson J, et al. Symptomatic vitamin E deficiency in cystic fibrosis. Arch Dis Child. 1985;60:162–4.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Wernicke C. Lehrbuch der Gehirnkrankheiten fur Aerzte und Studirende. Kassel: Theodor Fisher; 1881.Google Scholar
  64. 64.
    Rothrock JF, Smith MS. Wernicke’s disease complicating surgical therapy for morbid obesity. J Clin Neuroophthalmol. 1981;1:195–9.PubMedGoogle Scholar
  65. 65.
    Aasheim ET, Bjorkman S, Sevik TT, et al. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am J Clin Nutr. 2009;90:15–22.PubMedCrossRefGoogle Scholar
  66. 66.
    Aasheim ET. Wernicke encephalopathy after bariatric surgery: a systematic review. Ann Surg. 2008;248:714–20.PubMedGoogle Scholar
  67. 67.
    Kramer LD, Locke GE. Wernicke’s encephalopathy. Complication of gastric plication. J Clin Gastroenterol. 1987;9:549–52.PubMedCrossRefGoogle Scholar
  68. 68.
    Koike H, Misu K, Hattori N, et al. Postgastrectomy polyneuropathy with thiamine deficiency. J Neurol Neurosurg Psychiatry. 2001;71:357–62.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Berger JR, Singhal D. The neurologic complications of bariatric surgery. Handb Clin Neurol. 2014;120:587–94.PubMedCrossRefGoogle Scholar
  70. 70.
    Anderes E, Nand S. Commonly used drugs in hematologic disorders. Handb Clin Neurol. 2014;120:1125–39.PubMedCrossRefGoogle Scholar
  71. 71.
    Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc. 2006;81:1371–84.PubMedCrossRefGoogle Scholar
  72. 72.
    Kumar N, Gross Jr JB, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute degeneration. Neurology. 2004;63:33–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Kumar N, Ahlskog JE, Klein CJ, et al. Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology. 2006;48:78–83.PubMedCrossRefGoogle Scholar
  74. 74.
    Abarbanel JM, Berginer VM, Osimani A, et al. Neurologic complications after gastric restriction surgery for morbid obesity. Neurology. 1987;37:196–200.PubMedCrossRefGoogle Scholar
  75. 75.
    Peters G, du Plessis DG, Humphrey PR. Cerebral Whipple’s disease with a stroke-like presentation and cerebrovascular pathology. J Neurol Neurosurg Psychiatry. 2002;73:336–9.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Lagier J-C, Fenollar F, Lepidi H, et al. Failure and relapse after treatment with trimethoprim/sulfamethoxazole in classic Whipple’s disease. J Antimicrob Chemother. 2010;65:2005–12.PubMedCrossRefGoogle Scholar
  77. 77.
    Cirignotta F, Manconi M, Mondini S, et al. Wernicke-Korsakoff encephalopathy and polyneuropathy after gastroplasty for morbid obesity: report of a case. Arch Neurol. 2000;57:1356–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Compain C, Sacre K, Puéchal X, et al. Central nervous system involvement in Whipple disease: clinical study of 18 patients and long-term follow-up. Medicine. 2013;92:324–30.PubMedCrossRefGoogle Scholar
  79. 79.•
    Mohamed W, Neil E, Kupsky WJ, et al. Isolated intracranial Whipple's disease—report of a rare case and review of the literature. J Neurol Sci. 2011;308:1–8. A case report and systematic review of 24 cases of isolated intracranial presentation of Whipple’s disease. Most cases had a rapidly progressive atypical dementia.PubMedCrossRefGoogle Scholar
  80. 80.
    Blanc F, Ben Abdelghani K, Schramm F, et al. Whipple limbic encephalitis. Arch Neurol. 2011;68:1471–3.PubMedCrossRefGoogle Scholar
  81. 81.
    Black DF, Aksamit AJ, Morris JM. MR imaging of central nervous system Whipple disease: a 15-year review. AJNR. 2010;31:1493–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Hadjivassiliou M, Duker AP, Sanders DS. Gluten-related neurologic dysfunction. Handb Clin Neurol. 2014;120:607–19.PubMedCrossRefGoogle Scholar
  83. 83.
    Briani C, Zara G, Alaedini A, et al. Neurological complications of coeliac disease and autoimmune mechanisms: a prospective study. J Neuroimmunol. 2008;195:171–5.PubMedCrossRefGoogle Scholar
  84. 84.
    Hadjivassiliou M, Maki M, Sanders DS, et al. Autoantibody targeting of Brain. and intestinal transglutaminase in gluten ataxia. Neurology. 2006;66:373–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Hadjivassiliou M, Aeschlimann P, Strigun A, et al. Autoantibodies in gluten ataxia recognise a novel neuronal transglutaminase. Ann Neurol. 2008;64:332–43.PubMedCrossRefGoogle Scholar
  86. 86.
    Hadjivassiliou M, Grunewald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological and neuropathological characteristics of gluten ataxia. Lancet. 1998;352:1582–5.PubMedCrossRefGoogle Scholar
  87. 87.
    Hadjivassiliou M, Sanders DS, Woodroofe N, et al. Gluten ataxia. Cerebellum. 2008;7:494–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Deconinck N, Scaillon M, Segers V, et al. Opsoclonus-myoclonus associated with celiac disease. Pediatr Neurol. 2006;34:312–4.PubMedCrossRefGoogle Scholar
  89. 89.
    Hadjivassiliou M, Davies-Jones GAB, Sanders DS, et al. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry. 2003;74:1221–4.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.•
    Currie S, Hadjivassiliou M, Clark MJ, et al. Should we be ‘nervous’ about coeliac disease? Brain. abnormalities in patients with coeliac disease referred for neurological opinion. J Neurol Neurosurg Psychiatry. 2012;83:1216–21. A detailed quantified MR study indicating that patients with gluten sensitivity have decreased cerebellar volume and other MR abnormalities.PubMedCrossRefGoogle Scholar
  91. 91.
    Hadjivassiliou M, Grünewald RAG, Lawden M, et al. Headache and CNS white matter abnormalities associated with gluten sensitivity. Neurology. 2001;56:5–388.Google Scholar
  92. 92.
    Hu WT, Murray JA, Greenway MC, et al. Cognitive impairment and celiac disease. Arch Neurol. 2006;63:1440–6.PubMedCrossRefGoogle Scholar
  93. 93.
    Ludvigsson JF, Zingone F, Tomson T, et al. Increased risk of epilepsy in biopsy-verified celiac disease: a population-based cohort study. Neurology. 2012;78:1401–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Gobbi G. Coeliac disease, epilepsy and cerebral calcifications. Brain Dev. 2005;27:189–200.PubMedCrossRefGoogle Scholar
  95. 95.
    Luostarinen L, Himanen SL, Luostarinen M, et al. Neuromuscular and sensory disturbances in patients with well treated celiac disease. J Neurol Neurosurg Psychiatry. 2003;74:490–4.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Hadjivassiliou M, Grunewald RA, Kandler RH, et al. Neuropathy associated with gluten sensitivity. J Neurol Neurosurg Psychiatry. 2006;77:1262–6.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Hadjivassiliou M, Rao DS, Wharton SB, et al. Sensory ganglionopathy due to gluten sensitivity. Neurology. 2010;75:1003–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Henriksson KG, Hallert C, Norrby K, et al. Polymyositis and adult celiac disease. Acta Neurol Scand. 1982;65:301–19.PubMedCrossRefGoogle Scholar
  99. 99.
    Hadjivassiliou M, Chattopadhyay AK, Grunewald RA, et al. Myopathy associated with gluten sensitivity. Muscle Nerve. 2007;35:443–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Neurosciences, Service of Neurology, Hospital de Santa MariaUniversity of LisbonLisboaPortugal
  2. 2.Department of NeurologyHospital da LuzLisbonPortugal

Personalised recommendations